Su Jin Jang1, Joo Hyun Kang1, Tae Sup Lee1, Sung Joo Kim1, Kwang Il Kim1, Yong Jin Lee1, Gi Jeong Cheon2, Chang Woon Choi3, Sang Moo Lim3. 1. Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-gil, Gongneung-Dong, Nowon-Gu, Seoul, 139-706 Republic of Korea. 2. Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-gil, Gongneung-Dong, Nowon-Gu, Seoul, 139-706 Republic of Korea ; Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-gil, Gongneung-Dong, Nowon-Gu, Seoul, 139-706 Republic of Korea. 3. Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-gil, Gongneung-Dong, Nowon-Gu, Seoul, 139-706 Republic of Korea.
Abstract
OBJECTIVE: We determined the cytotoxic properties of cytochrome P450 4B1 (CYP4B1) activated 4-ipomeanol (4-ipo) and 2-aminoanthracene (2-AA) in rat glioma to verify the CYP4B1/4-ipo or 2-AA system for prodrug-activating gene therapy. METHODS: The cyp4B1 cDNA was cloned into pcDNA3.1/Hygro from rabbit lung total RNA (pcDNA-cyp4B1). Lentiviral vector encoding firefly luciferase (fLuc) was infected into C6 (rat glioma), and the fLuc-expressing cell was selected (C6-L). After transfection with pcDNA-cyp4B1 vector into C6-L, the single clone expressing cyp4B1 gene was selected (C6-CL). Prodrug for various concentrations of 4-ipo or 2-AA was treated for 72 h and 96 h. The cell survival rate of C6-CL was determined using MTT assay and trypan-blue dye exclusion methods. RESULTS: By RT-PCR analysis, fLuc and CYP4B1 expression was detected in C6-CL, but not in C6. MTT assay and trypan-blue dye exclusion showed that IC50 of C6-CL was 0.3 mM and <0.01 mM after 4-ipo or 2-AA treatment at 96 h or 72 h exposure, respectively. Cell survivals of C6-CL were more rapidly reduced after treatment with 4-ipo or 2-AA than those of C6-L cells. The cell survival rate with MTT and trypan-blue dye exclusion assay was well correlated with fLuc activity in C6-CL cells. CONCLUSION: CYP4B1-based prodrug-activating gene therapy may have the potential to treat glioma and the cytotoxic effects of CYP4B1 enzyme activated 4-ipo or 2-AA in C6, and could be clearly determined by bioluminescent activity in C6-CL.
OBJECTIVE: We determined the cytotoxic properties of cytochrome P450 4B1 (CYP4B1) activated 4-ipomeanol (4-ipo) and 2-aminoanthracene (2-AA) in ratglioma to verify the CYP4B1/4-ipo or 2-AA system for prodrug-activating gene therapy. METHODS: The cyp4B1 cDNA was cloned into pcDNA3.1/Hygro from rabbit lung total RNA (pcDNA-cyp4B1). Lentiviral vector encoding firefly luciferase (fLuc) was infected into C6 (ratglioma), and the fLuc-expressing cell was selected (C6-L). After transfection with pcDNA-cyp4B1 vector into C6-L, the single clone expressing cyp4B1 gene was selected (C6-CL). Prodrug for various concentrations of 4-ipo or 2-AA was treated for 72 h and 96 h. The cell survival rate of C6-CL was determined using MTT assay and trypan-blue dye exclusion methods. RESULTS: By RT-PCR analysis, fLuc and CYP4B1 expression was detected in C6-CL, but not in C6. MTT assay and trypan-blue dye exclusion showed that IC50 of C6-CL was 0.3 mM and <0.01 mM after 4-ipo or 2-AA treatment at 96 h or 72 h exposure, respectively. Cell survivals of C6-CL were more rapidly reduced after treatment with 4-ipo or 2-AA than those of C6-L cells. The cell survival rate with MTT and trypan-blue dye exclusion assay was well correlated with fLuc activity in C6-CL cells. CONCLUSION:CYP4B1-based prodrug-activating gene therapy may have the potential to treat glioma and the cytotoxic effects of CYP4B1 enzyme activated 4-ipo or 2-AA in C6, and could be clearly determined by bioluminescent activity in C6-CL.
Authors: W B Parker; S A King; P W Allan; L L Bennett; J A Secrist; J A Montgomery; K S Gilbert; W R Waud; A H Wells; G Y Gillespie; E J Sorscher Journal: Hum Gene Ther Date: 1997-09-20 Impact factor: 5.695
Authors: N G Rainov; M Sena-Esteves; C Fraefel; K U Dobberstein; E A Chiocca; X O Breakefield Journal: Adv Exp Med Biol Date: 1998 Impact factor: 2.622
Authors: Aaron M Teitelbaum; Matthew G McDonald; John P Kowalski; Oliver T Parkinson; Michele Scian; Dale Whittington; Katharina Roellecke; Helmut Hanenberg; Constanze Wiek; Allan E Rettie Journal: J Pharmacol Exp Ther Date: 2018-11-08 Impact factor: 4.030
Authors: Katharina Roellecke; Vera D Jäger; Veselin H Gyurov; John P Kowalski; Stephanie Mielke; Allan E Rettie; Helmut Hanenberg; Constanze Wiek; Marco Girhard Journal: Protein Eng Des Sel Date: 2017-03-01 Impact factor: 1.650